drugset / Trial / NCT02232776

Efficacy and Safety of Losartan in Children With Ig A Nephropathy

NCT02232776

NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.

Timeline

Start
2014-10
Primary completion
2016-12
Completion
2017-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 0.7 mg/kg